Complete Up To Date Information about Soxisol Tablets.
NADA Number: 007-981 | |
| Proprietary Name |
Soxisol Tablets |
|---|---|
| Sponsor |
Fort Dodge Animal Health, Division of Wyeth |
| Sponsor Address |
800 Fifth Street NW Fort Dodge, IA 50501 USA |
| Ingredients |
Sulfisoxazole |
| Species |
Cat, no use class stated or implied Dog, no use class stated or implied |
| Routes of Administration |
Per Os |
| Dose Form |
Tablet |
| Drug Form |
Tablet |
| Dispensing Status |
OTC |
|
Dosage Amount, Indications & Limitations |
520.2330 Sulfisoxazole tablets. Specifications: Each tablet contains 260 milligrams (4 grains) of sulfisoxazole. Conditions of use: Dogs Amount: Administer one tablet orally per 4 pounds of body weight. Indications: Use in dogs as an aid in treatment of bacterial pneumonia and bacterial enteritis when caused by organisms sensitive to sulfisoxazole. Limitations: Repeat dosage at 24-hour intervals until 2 to 3 days after disappearance of clinical symptoms. (Administration of one-half daily dosage at 12-hour intervals or one-third daily dosage at intervals will provide a more constant blood level.) Provide adequate supply of drinking water. If symptoms persist after using this preparation for 2 or 3 days, consult a veterinarian. Cats Amount: Administer one tablet orally per 4 pounds of body weight. Indications: Use in cats as an aid in treatment of bacterial pneumonia and bacterial enteritis when caused by organisms sensitive to sulfisoxazole. Limitations: Repeat dosage at 24-hour intervals until 2 to 3 days after disappearance of clinical symptoms. (Administration of one-half daily dosage at 12-hour intervals or one-third daily dosage at intervals will provide a more constant blood level.) Provide adequate supply of drinking water. If symptoms persist after using this preparation for 2 or 3 days, consult a veterinarian. NAS/NRC status: These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by 514.111 of this chapter, but may require bioequivalency and safety information. |